Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21503526 | 0.85 | CNR1 (0.36) | CYP2C9CNR1CNR2FFAR1 | |
| SCHEMBL13017062 | 0.82 | L3MBTL1 (0.49) | CYP1A2CYP2C9CYP2C19CNR2 | |
| SCHEMBL12949847 | 0.81 | RXRA (0.39) | ENPP2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5532478 | 0.79 | ACACB (0.45) | ACACB | |
| SCHEMBL24974314 | 0.78 | DAO (0.47) | FFAR1ACACB | |
| SCHEMBL21503605 | 0.78 | SMN1; SMN2 (0.39) | ENPP2CYP1A2CYP3A4 | |
| SCHEMBL2093848 | 0.78 | ENPP2 (0.40) | SCN10AENPP2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21922351 | 0.77 | ENPP2 (0.37) | ENPP2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24401039 | 0.77 | LOXL2 (0.37) | SCN10AENPP2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24974030 | 0.77 | MLNR (0.41) | FFAR1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | SCN10A 4640/4885ENPP2 2289/4885CYP1A2 1111/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | SCN10A 4640/4885ENPP2 2289/4885CYP1A2 1111/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | SCN10A 4640/4885ENPP2 2289/4885CYP1A2 1111/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | SCN10A 4640/4885ENPP2 2289/4885CYP1A2 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.